Stifel analyst Thomas Stephan lowered the firm’s price target on Staar Surgical to $45 from $50 and keeps a Hold rating on the shares. With top-line growth expectations reset, the low-end of the 15%-20% outlook represents “a fairly solid floor,” but the firm continues to “struggle with where more meaningful upside to numbers (and the multiple) exists from here,” the analyst tells investors following a review of the company’s Q2 10-Q report.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on STAA:
- Staar Surgical to replace Urstadt Biddle in S&P 600 at open on 8/22
- Dolby to replace Staar Surgical in S&P 400 at open on 8/22
- Staar Surgical price target lowered to $57 from $71 at Stephens
- Staar Surgical price target lowered to $50 from $65 at Piper Sandler
- Staar Surgical price target lowered to $58 from $75 at Needham
